REGN logo

REGN EBITDA

annual EBITDA:

$5.32B+$624.70M(+13.31%)
December 31, 2024

Summary

  • As of today (June 26, 2025), REGN annual EBITDA is $5.32 billion, with the most recent change of +$624.70 million (+13.31%) on December 31, 2024.
  • During the last 3 years, REGN annual EBITDA has fallen by -$4.35 billion (-45.00%).
  • REGN annual EBITDA is now -45.00% below its all-time high of $9.67 billion, reached on December 31, 2021.

Performance

REGN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

quarterly EBITDA:

$1.04B-$54.40M(-4.97%)
March 31, 2025

Summary

  • As of today (June 26, 2025), REGN quarterly EBITDA is $1.04 billion, with the most recent change of -$54.40 million (-4.97%) on March 31, 2025.
  • Over the past year, REGN quarterly EBITDA has increased by +$209.70 million (+25.24%).
  • REGN quarterly EBITDA is now -72.89% below its all-time high of $3.84 billion, reached on June 30, 2021.

Performance

REGN quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

TTM EBITDA:

$5.53B+$209.70M(+3.94%)
March 31, 2025

Summary

  • As of today (June 26, 2025), REGN TTM EBITDA is $5.53 billion, with the most recent change of +$209.70 million (+3.94%) on March 31, 2025.
  • Over the past year, REGN TTM EBITDA has increased by +$979.00 million (+21.52%).
  • REGN TTM EBITDA is now -42.83% below its all-time high of $9.67 billion, reached on December 31, 2021.

Performance

REGN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

REGN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+13.3%+25.2%+21.5%
3 y3 years-45.0%-9.4%-41.7%
5 y5 years+99.2%+42.4%+97.7%

REGN EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-45.0%+13.3%-41.0%+25.2%-41.7%+21.5%
5 y5-year-45.0%+99.2%-72.9%+42.4%-42.8%+97.7%
alltimeall time-45.0%+3218.6%-72.9%+2123.8%-42.8%+3341.5%

REGN EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
$1.04B(-5.0%)
$5.53B(+3.9%)
Dec 2024
$5.32B(+13.3%)
$1.09B(-32.8%)
$5.32B(-3.3%)
Sep 2024
-
$1.63B(-7.7%)
$5.50B(+7.7%)
Jun 2024
-
$1.76B(+112.3%)
$5.11B(+12.3%)
Mar 2024
-
$830.90M(-35.0%)
$4.55B(-3.1%)
Dec 2023
$4.69B(-10.8%)
$1.28B(+3.6%)
$4.69B(-3.4%)
Sep 2023
-
$1.23B(+2.4%)
$4.86B(-7.3%)
Jun 2023
-
$1.20B(+23.5%)
$5.24B(+3.0%)
Mar 2023
-
$975.50M(-32.4%)
$5.09B(-3.3%)
Dec 2022
$5.26B(-45.6%)
$1.44B(-10.8%)
$5.26B(-17.9%)
Sep 2022
-
$1.62B(+54.0%)
$6.41B(-4.3%)
Jun 2022
-
$1.05B(-8.6%)
$6.70B(-29.4%)
Mar 2022
-
$1.15B(-55.7%)
$9.48B(-1.9%)
Dec 2021
$9.67B(+135.7%)
$2.59B(+36.1%)
$9.67B(+15.4%)
Sep 2021
-
$1.90B(-50.4%)
$8.38B(+10.9%)
Jun 2021
-
$3.84B(+187.5%)
$7.56B(+60.6%)
Mar 2021
-
$1.33B(+2.6%)
$4.71B(+14.7%)
Dec 2020
$4.10B(+53.7%)
$1.30B(+20.0%)
$4.10B(+9.3%)
Sep 2020
-
$1.08B(+9.8%)
$3.75B(+7.3%)
Jun 2020
-
$987.40M(+35.1%)
$3.50B(+25.1%)
Mar 2020
-
$730.80M(-23.1%)
$2.80B(+4.7%)
Dec 2019
$2.67B(-2.2%)
$950.80M(+14.7%)
$2.67B(+9.2%)
Sep 2019
-
$829.20M(+191.2%)
$2.45B(+6.6%)
Jun 2019
-
$284.80M(-52.9%)
$2.29B(-15.2%)
Mar 2019
-
$604.80M(-16.7%)
$2.71B(-0.9%)
Dec 2018
$2.73B(+21.4%)
$726.40M(+7.0%)
$2.73B(+5.0%)
Sep 2018
-
$678.70M(-2.6%)
$2.60B(+2.7%)
Jun 2018
-
$696.60M(+10.9%)
$2.53B(+5.4%)
Mar 2018
-
$628.20M(+5.5%)
$2.40B(+6.7%)
Dec 2017
$2.25B(+56.0%)
$595.31M(-2.3%)
$2.25B(+11.0%)
Sep 2017
-
$609.51M(+7.6%)
$2.03B(+11.9%)
Jun 2017
-
$566.38M(+18.5%)
$1.81B(+15.8%)
Mar 2017
-
$477.90M(+28.1%)
$1.56B(+8.5%)
Dec 2016
$1.44B(+9.7%)
$373.18M(-5.3%)
$1.44B(+10.4%)
Sep 2016
-
$394.22M(+23.8%)
$1.31B(-1.6%)
Jun 2016
-
$318.54M(-10.5%)
$1.33B(-3.2%)
Mar 2016
-
$355.77M(+49.8%)
$1.37B(+4.3%)
Dec 2015
$1.31B(+54.4%)
$237.44M(-42.8%)
$1.31B(+2.1%)
Sep 2015
-
$415.24M(+14.8%)
$1.29B(+19.5%)
Jun 2015
-
$361.81M(+20.7%)
$1.08B(+13.7%)
Mar 2015
-
$299.76M(+42.6%)
$947.02M(+11.2%)
Dec 2014
$851.29M(+8.6%)
$210.21M(+2.5%)
$851.29M(+0.7%)
Sep 2014
-
$205.06M(-11.6%)
$845.21M(-4.9%)
Jun 2014
-
$232.00M(+13.7%)
$888.38M(+7.7%)
Mar 2014
-
$204.03M(-0.0%)
$825.14M(+5.2%)
Dec 2013
$784.02M(+57.9%)
$204.13M(-17.8%)
$784.02M(+6.6%)
Sep 2013
-
$248.22M(+47.1%)
$735.73M(+5.1%)
Jun 2013
-
$168.76M(+3.6%)
$699.71M(+11.4%)
Mar 2013
-
$162.91M(+4.5%)
$628.35M(+26.5%)
Dec 2012
$496.67M(-391.3%)
$155.83M(-26.6%)
$496.67M(+63.3%)
Sep 2012
-
$212.21M(+117.9%)
$304.16M(+616.0%)
Jun 2012
-
$97.40M(+211.9%)
$42.48M(-139.9%)
Mar 2012
-
$31.23M(-185.1%)
-$106.33M(-37.6%)
Dec 2011
-$170.53M(+125.4%)
-$36.68M(-25.9%)
-$170.53M(+21.9%)
Sep 2011
-
-$49.47M(-3.8%)
-$139.90M(+19.4%)
Jun 2011
-
-$51.42M(+56.0%)
-$117.19M(+38.9%)
Mar 2011
-
-$32.97M(+444.6%)
-$84.37M(+11.5%)
Dec 2010
-$75.66M(+36.7%)
-$6.05M(-77.4%)
-$75.66M(-24.0%)
Sep 2010
-
-$26.75M(+43.7%)
-$99.59M(+41.2%)
Jun 2010
-
-$18.61M(-23.3%)
-$70.55M(+8.2%)
Mar 2010
-
-$24.25M(-19.1%)
-$65.21M(+21.6%)
Dec 2009
-$55.37M(-4.1%)
-$29.98M(-1404.3%)
-$53.62M(+54.1%)
Sep 2009
-
$2.30M(-117.3%)
-$34.80M(-35.9%)
Jun 2009
-
-$13.27M(+4.8%)
-$54.26M(-5.9%)
Mar 2009
-
-$12.66M(+13.4%)
-$57.67M(-0.5%)
Dec 2008
-$57.74M(-29.6%)
-$11.17M(-34.9%)
-$57.97M(+67.8%)
Sep 2008
-
-$17.16M(+2.9%)
-$34.54M(-35.1%)
Jun 2008
-
-$16.68M(+28.6%)
-$53.19M(-17.2%)
Mar 2008
-
-$12.96M(-205.7%)
-$64.24M(-21.7%)
Dec 2007
-$82.07M
$12.26M(-134.2%)
-$82.07M(-34.0%)
DateAnnualQuarterlyTTM
Sep 2007
-
-$35.81M(+29.1%)
-$124.42M(+9.9%)
Jun 2007
-
-$27.73M(-9.9%)
-$113.16M(+6.8%)
Mar 2007
-
-$30.79M(+2.3%)
-$105.99M(+13.9%)
Dec 2006
-$93.06M(-166.5%)
-$30.09M(+22.6%)
-$93.06M(-158.1%)
Sep 2006
-
-$24.55M(+19.4%)
$160.22M(+3.8%)
Jun 2006
-
-$20.56M(+15.1%)
$154.32M(+5.3%)
Mar 2006
-
-$17.86M(-108.0%)
$146.54M(+4.7%)
Dec 2005
$139.93M(+566.1%)
$223.19M(-832.9%)
$139.93M(-285.6%)
Sep 2005
-
-$30.45M(+7.5%)
-$75.38M(+49.2%)
Jun 2005
-
-$28.34M(+15.7%)
-$50.53M(+62.8%)
Mar 2005
-
-$24.48M(-410.3%)
-$31.04M(-247.8%)
Dec 2004
$21.01M(-124.1%)
$7.89M(-240.8%)
$21.01M(+7070.0%)
Sep 2004
-
-$5.60M(-36.7%)
$293.00K(-101.8%)
Jun 2004
-
-$8.85M(-132.1%)
-$16.15M(-51.3%)
Mar 2004
-
$27.57M(-314.9%)
-$33.18M(-61.8%)
Dec 2003
-$87.05M(-23.3%)
-$12.82M(-41.8%)
-$86.84M(-18.5%)
Sep 2003
-
-$22.05M(-14.8%)
-$106.60M(-6.9%)
Jun 2003
-
-$25.88M(-0.8%)
-$114.56M(-1.6%)
Mar 2003
-
-$26.09M(-19.9%)
-$116.40M(+2.6%)
Dec 2002
-$113.50M(+42.6%)
-$32.58M(+8.6%)
-$113.50M(+4.4%)
Sep 2002
-
-$30.01M(+8.2%)
-$108.70M(+8.2%)
Jun 2002
-
-$27.72M(+19.6%)
-$100.47M(+12.4%)
Mar 2002
-
-$23.18M(-16.5%)
-$89.41M(+12.3%)
Dec 2001
-$79.61M(+281.7%)
-$27.78M(+27.6%)
-$79.61M(+32.0%)
Sep 2001
-
-$21.77M(+30.7%)
-$60.32M(+14.1%)
Jun 2001
-
-$16.67M(+24.5%)
-$52.87M(+35.4%)
Mar 2001
-
-$13.38M(+57.6%)
-$39.05M(+17.5%)
Dec 2000
-$20.86M(+2.2%)
-$8.49M(-40.7%)
-$33.22M(+35.4%)
Sep 2000
-
-$14.33M(+405.2%)
-$24.52M(+70.4%)
Jun 2000
-
-$2.84M(-62.4%)
-$14.39M(-24.5%)
Mar 2000
-
-$7.55M(-3877.0%)
-$19.05M(-10.1%)
Dec 1999
-$20.40M(+114.7%)
$200.00K(-104.8%)
-$21.20M(-20.6%)
Sep 1999
-
-$4.20M(-44.0%)
-$26.70M(+10.3%)
Jun 1999
-
-$7.50M(-22.7%)
-$24.20M(+59.2%)
Mar 1999
-
-$9.70M(+83.0%)
-$15.20M(+60.0%)
Dec 1998
-$9.50M(+2.2%)
-$5.30M(+211.8%)
-$9.50M(+17.3%)
Sep 1998
-
-$1.70M(-213.3%)
-$8.10M(+24.6%)
Jun 1998
-
$1.50M(-137.5%)
-$6.50M(-38.1%)
Mar 1998
-
-$4.00M(+2.6%)
-$10.50M(+11.7%)
Dec 1997
-$9.30M(-17.0%)
-$3.90M(+3800.0%)
-$9.40M(+11.9%)
Sep 1997
-
-$100.00K(-96.0%)
-$8.40M(-25.0%)
Jun 1997
-
-$2.50M(-13.8%)
-$11.20M(+2.8%)
Mar 1997
-
-$2.90M(0.0%)
-$10.90M(-2.7%)
Dec 1996
-$11.20M(+558.8%)
-$2.90M(0.0%)
-$11.20M(+15.5%)
Sep 1996
-
-$2.90M(+31.8%)
-$9.70M(+27.6%)
Jun 1996
-
-$2.20M(-31.3%)
-$7.60M(+46.2%)
Mar 1996
-
-$3.20M(+128.6%)
-$5.20M(+108.0%)
Dec 1995
-$1.70M(-93.2%)
-$1.40M(+75.0%)
-$2.50M(-50.0%)
Sep 1995
-
-$800.00K(-500.0%)
-$5.00M(-26.5%)
Jun 1995
-
$200.00K(-140.0%)
-$6.80M(-57.5%)
Mar 1995
-
-$500.00K(-87.2%)
-$16.00M(-36.0%)
Dec 1994
-$25.00M(-30.0%)
-$3.90M(+50.0%)
-$25.00M(-20.4%)
Sep 1994
-
-$2.60M(-71.1%)
-$31.40M(-15.8%)
Jun 1994
-
-$9.00M(-5.3%)
-$37.30M(-0.3%)
Mar 1994
-
-$9.50M(-7.8%)
-$37.40M(+2.7%)
Dec 1993
-$35.70M(+119.0%)
-$10.30M(+21.2%)
-$36.40M(+15.2%)
Sep 1993
-
-$8.50M(-6.6%)
-$31.60M(+12.1%)
Jun 1993
-
-$9.10M(+7.1%)
-$28.20M(+27.6%)
Mar 1993
-
-$8.50M(+54.5%)
-$22.10M(+34.8%)
Dec 1992
-$16.30M(+85.2%)
-$5.50M(+7.8%)
-$16.40M(+14.7%)
Sep 1992
-
-$5.10M(+70.0%)
-$14.30M(+24.3%)
Jun 1992
-
-$3.00M(+7.1%)
-$11.50M(+11.7%)
Mar 1992
-
-$2.80M(-17.6%)
-$10.30M(+87.3%)
Dec 1991
-$8.80M(+193.3%)
-$3.40M(+47.8%)
-$5.50M(-39.6%)
Sep 1991
-
-$2.30M(+27.8%)
-$9.10M(+65.5%)
Jun 1991
-
-$1.80M(-190.0%)
-$5.50M(+120.0%)
Mar 1991
-
$2.00M(-128.6%)
-$2.50M(-24.2%)
Dec 1990
-$3.00M
-$7.00M(-638.5%)
-$3.30M(-189.2%)
Sep 1990
-
$1.30M(+8.3%)
$3.70M(+54.2%)
Jun 1990
-
$1.20M(0.0%)
$2.40M(+100.0%)
Mar 1990
-
$1.20M
$1.20M

FAQ

  • What is Regeneron Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Regeneron Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?

What is Regeneron Pharmaceuticals annual EBITDA?

The current annual EBITDA of REGN is $5.32B

What is the all time high annual EBITDA for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual EBITDA is $9.67B

What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, REGN annual EBITDA has changed by +$624.70M (+13.31%)

What is Regeneron Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of REGN is $1.04B

What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly EBITDA is $3.84B

What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, REGN quarterly EBITDA has changed by +$209.70M (+25.24%)

What is Regeneron Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of REGN is $5.53B

What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high TTM EBITDA is $9.67B

What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, REGN TTM EBITDA has changed by +$979.00M (+21.52%)
On this page